Immortalized p19ARF null hepatocytes restore liver injury and generate hepatic progenitors after transplantation.
Primary hepatocytes are blocked in mitotic activity and well-defined culture conditions only allow the limited expansion of these cells. Various genetic modifications have therefore been employed to establish immortalized hepatic cell lines, but, unfortunately, proper hepatocyte cultures conducting a faithful hepatic gene expression program and lacking malignancy are hardly available. Here we report the immortalization of primary hepatocytes isolated from p19(ARF) null mice using the rationale that loss of p19(ARF) lowers growth-suppressive functions of p53 and bypasses cellular senescence without losing genetic stability. The established hepatocytes, called MIM, express liver-specific markers, show a nontumorigenic phenotype, and competence to undergo Fas-mediated apoptosis. Intrasplenic transplantation of GFP-expressing parental MIM cells into Fas-injured livers of SCID mice revealed liver-reconstituting activity. In the regenerated liver, MIM cells localized in small-sized clusters and showed presence in structures comparable to canals of Hering, the site of oval cells. Transplantation of MIM-Bcl-X(L) cells, which are protected against apoptosis, and successive Fas-induced liver damage, enhanced donor-derived liver repopulation by showing differentiation into cholangiocytes and cells expressing markers characteristic of both fetal hepatocytes and oval cells. In conclusion, these data indicate that long-term cultivated p19(ARF) null hepatocytes are capable of generating hepatic progenitor cells during liver restoration, and thus represent a highly valuable tool to study the differentiation repertoire of hepatocytes.
Institute of Cancer Research, University of Vienna, Borschke-Gasse 8a, A-1090 Vienna, Austria.
Mario
M
Mikula
Eva
E
Fuchs
Heidemarie
H
Huber
Hartmut
H
Beug
Rolf
R
Schulte-Hermann
Wolfgang
W
Mikulits
D000818:Animals; D002455:Cell Division; D002461:Cell Line, Transformed; D019941:Cyclin-Dependent Kinase Inhibitor p16; D006500:Hepatic Duct, Common / Q000473:pathology; D022781:Hepatocytes / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation*; D008099:Liver / Q000473:pathology*; D008107:Liver Diseases / Q000276:immunology / Q000601:surgery*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D013154:Spleen / Q000601:surgery; D013234:Stem Cells / Q000473:pathology*; D016042:Transplantation, Heterotopic; D025803:Tumor Suppressor Protein p14ARF / Q000172:deficiency*; D019014:fas Receptor / Q000276:immunology
C417743:Cdkn2a protein, mouse; D019941:Cyclin-Dependent Kinase Inhibitor p16; D025803:Tumor Suppressor Protein p14ARF; D019014:fas Receptor